NeuroPhet wins 2 categories at 'BioSpectrum Asia Excellence Awards 2026'
Predicted impact: Low· Actual: −2.5% vs sector, volume 0.3× normal (5 trading days)
Industry award wins; no financial relevance to the share price.
Neurophet뉴로핏
380550 · KOSDAQ · ₩380550 · 뉴로핏
₩6,540▲ ₩900 (15.96%)End-of-day · Oct 26, 2026 · End-of-day prices.
Price · 1Y −67.25%
- Market cap
- ₩80B
- Enterprise value
- ₩41B
- P/E
- —
- P/B
- 2.3×
- Dividend yield
- 0.0%
- ROE
- −65.2%
- Net margin
- −889.1%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−82.2% from the high
₩5,480Today: ₩5,520 – ₩7,330₩36,700
Returns
- 1W+4.0%
- 1M−15.5%
- 3M−16.3%
- 6M−70.3%
- YTD−70.6%
- 1Y−68.1%
- Volume today
- 4,139,031
- 27.7× the 20-day average
- Traded today
- ₩29B
- Listed shares
- 12,198,866
- EPS (12 months)
- −₩1,887
- Earnings yield −28.9%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Why is it moving?
+16.0% on Oct 26, 2026. Trading value 25.4× its normal.
- • Foreign investors sold a net ₩1.4B that day
- • Buzz 81 on JONBUR: heavy trading
We found no news, filing or broker report explaining it yet. Moves without news happen; it may come later.
Possible reasons, not certainties. Not financial advice.
Signals
Buzzing- BuzzHighBuzz 81: heavy trading.
- MomentumWeak-10.4% over the last month; the price is below its 20-day average.
- News impactLow1 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Neurophet stock overview
Neurophet (뉴로핏, KRX: 380550) is listed on KOSDAQ, in the Software sector. The company develops AI-based brain MRI and PET imaging analysis software for diagnosing neurodegenerative brain diseases, with a focus on Alzheimer's disease, and also offers brain stimulation treatment design and devices. Its shares closed at ₩6,540 on Oct 26, 2026, up 15.96% on the day, giving it a market value of ₩80B.
Key facts
- Market cap
- ₩80B
- Sector
- Software
- Latest price change
- +15.96%
- As of
- Oct 26, 2026
- Main business
- The company develops AI-based brain MRI and PET imaging analysis software for diagnosing neurodegenerative brain diseases, with a focus on Alzheimer's disease, and also offers brain stimulation treatment design and devices.
Quick answers about Neurophet
- What does Neurophet do?
- The company develops AI-based brain MRI and PET imaging analysis software for diagnosing neurodegenerative brain diseases, with a focus on Alzheimer's disease, and also offers brain stimulation treatment design and devices. Its main products include Neurophet AQUA, SCALE PET, and AQUA AD, supplied to health screening centers and secondary and tertiary hospitals, and an Imaging CRO service provided to pharmaceutical and drug development companies for clinical trials. The company is expanding into overseas markets including Japan, China, and the United States.
- What is the market cap of Neurophet?
- The market capitalisation of Neurophet was ₩80B at the close on Oct 26, 2026.
- Who are the largest shareholders of Neurophet?
- According to the latest official filings, the largest reported holders are Kim Dong-hyeon (27.46%, as of Jun 1, 2026); Bin Jun-gil (9.74%, as of Jun 1, 2026); SBI Investment (4.22%, as of Sep 4, 2025).
- When is the next earnings report from Neurophet?
- Korean companies rarely announce results dates in advance. Based on when Neurophet filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Neurophet?
- Yes. The National Pension Service held 0.80% of Neurophet shares as of Dec 31, 2025.
Company profile
The company develops AI-based brain MRI and PET imaging analysis software for diagnosing neurodegenerative brain diseases, with a focus on Alzheimer's disease, and also offers brain stimulation treatment design and devices. Its main products include Neurophet AQUA, SCALE PET, and AQUA AD, supplied to health screening centers and secondary and tertiary hospitals, and an Imaging CRO service provided to pharmaceutical and drug development companies for clinical trials. The company is expanding into overseas markets including Japan, China, and the United States.
Written by AI from the company's latest annual report.
- Korean name
- 뉴로핏
- Sector
- Software
- Themes
- AI healthcare
- CEO
- 빈준길, 김동현
- Founded
- Mar 2016
- Listed
- Jul 2025
- Listed shares
- 12,198,866
- Fiscal year ends
- Month 12
- Website
- www.neurophet.com/
Similar companies
- Hyundai Autoever307950 · ₩8.6T₩312,500−3.70%
- Krafton259960 · ₩8.4T₩183,500−1.13%
- NC036570 · ₩4.3T₩201,500−1.71%
- Netmarble251270 · ₩2.8T₩33,550−1.32%
- PearlAbyss263750 · ₩2.2T₩34,350−0.72%
- Shift UP462870 · ₩1.7T₩29,450−2.64%
- NHN181710 · ₩1.6T₩49,100−4.29%
- Kakao Games293490 · ₩1.2T₩11,200−3.03%
Recent news
Recent filings
See all- Change of Head Office LocationSep 17, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- [Amended] Notice of Stock Purchase Option GrantAug 4, 2026
- Notice on Grant of Stock Purchase OptionsAug 4, 2026
- Major sales or supply contractJun 10, 2026
Titles in Korean until English translations are added.
Also known as: Neurophet / 뉴로핏 / 380550 / KRX:380550
Source: KRX statistical information